BiVictriX Therapeutics PLC US Patent Granted (1361K)
August 23 2023 - 2:00AM
UK Regulatory
TIDMBVX
RNS Number : 1361K
BiVictriX Therapeutics PLC
23 August 2023
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
ARTICLE 7 OF THE EU REGULATION 596/2014 AS IT FORMS PART OF THE UK
LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").
UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY
INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE
PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")
US Patent Granted Providing Broad Protection for BVX001
Alderley Park, 23 August 2023 - BiVictriX Therapeutics plc (AIM:
BVX), an emerging biotechnology company applying a differentiated
approach to develop next-generation cancer therapies with
substantially improved cancer cell selectivity and anti-cancer
activity, announces that the United States Patent and Trademark
Office ("USPTO") has granted a patent providing broad protection
for the Company's lead asset, BVX001.
The claims granted within this patent (patent number
US11,732,040), which belongs to the wider patent family "Therapy"
currently being prosecuted in eight territories worldwide, provides
ultimate broad protection for the lead therapeutic asset, BVX001,
at the antigen level.
The claims granted in the United States provide broad protection
for an antibody-based therapeutic attached to a cell-killing
payload, such as an alternative Antibody Drug Conjugate ("ADC")
therapy or any akin therapeutic, which binds to the Company's
Bi-Cygni(R) twin antigen fingerprint comprising CD7 x CD33, for use
in treating of a CD7(+) CD33(+) haematological malignancy. The
coverage extends beyond the Company's lead indication of Acute
Myeloid Leukaemia ("AML"), providing protection across any
haematological cancer type which may be positive for CD7 and CD33.
This is true irrespective of the therapeutic format employed,
including use of alternative antibody sequences, alternative
antibody formats and/or alternative cell killing payloads, which
often represent routes taken by third parties to develop a
competitive therapeutic. Taken together, these granted claims
represent a very broad and commercially favourable position for
BiVictriX.
Further to the US patent issue, which follows the issuance of a
Notice of Allowance from the USPTO, announced in July 2023 ,
BiVictriX confirms receipt of an additional Notice of Allowance
from the Japanese Patent Office. The notice relates to the Japanese
patent (publication number JP2021504469) which also forms part of
the wider patent family, "Therapy". It is anticipated that this
patent will be granted in Japan in the coming weeks, providing
further protection for BVX001 at the broadest level. BiVictriX is
currently seeking approval for this patent family in an additional
six jurisdictions worldwide, with further patent grants expected in
the forthcoming months.
Tiffany Thorn, CEO of BiVictriX commented: "I am excited to
announce that our first patent has been granted in the United
States. This patent relates to our broadest patent family,
providing robust protection for BVX001 at the antigen level, across
multiple cancer types, and acts as a key milestone for the Company
demonstrating the breadth of patent protection we can achieve with
the Bi-Cygni(R) approach. This patent grant is expected to be the
first of many as we continue to prosecute the wider patent family
in seven further jurisdictions worldwide, creating a robust patent
protected portfolio.
Barbara Fleck, European Patent Attorney and Partner at Appleyard
Leads IP LLP commented: "I am very pleased to see that the USPTO
has issued BiVictriX's patent with broad claims to methods for
treating a CD7(+) CD33(+) haematological malignancy by
administering a cell inhibiting agent linked to a cytotoxin that
bispecifically binds to CD33 and CD7. Obtaining such broad claims
in the antibody space is challenging and this not only validates
BiVictriX's Bi-Cygni(R) ADC technology for the treatment of AML,
but also provides the Company with broad US patent coverage in a
competitive space."
ENDS
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non-Executive Chairman Email: info@bivictrix.com
SP Angel Corporate Finance LLP (NOMAD Tel: +44 (0) 20 3470
and Broker) 0470
David Hignell, Kasia Brzozowska (Corporate
Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886
Broker) 2500
Rupert Dearden/Freddy Crossley/Emma
Earl
Consilium Strategic Communications
Mary-Jane Elliott, Namrata Taak, Tel: +44 (0) 20 3709 5700
Max Bennett, Emmalee Hoppe Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX (AIM: BVX) is an emerging biotechnology company
leveraging clinical experience and its proprietary discovery engine
to advance a new class of highly cancer-selective, next-generation
precision cancer therapies in one of the fastest-growing markets in
oncology. BiVictriX's first-in-class Bi-Cygni(R) Antibody Drug
Conjugates ("ADCs") combine superior efficacy with substantially
improved cancer-selectivity and safety to provide opportunities for
prolonged dosing and greater efficacy in the clinic. The Company is
advancing its pipeline to deliver the future of cancer care across
a broad range of haematological and solid cancer indications in
areas of high unmet medical need.
Find out more at www.bivictrix.com and connect with us on
LinkedIn and Twitter @BiVictriX .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGZGZRLZMGFZM
(END) Dow Jones Newswires
August 23, 2023 02:00 ET (06:00 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Sep 2023 to Sep 2024